Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7016796 | 0.95 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1PKMTAAR1LMNA | |
| SCHEMBL31303986 | 0.90 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1PKMTAAR1LMNA | |
| Trifluoroacetic Acid SCHEMBL29174401 | 0.88 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1PKMTAAR1CPB2 | |
| SCHEMBL14696607 | 0.86 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1PKMTAAR1LMNA | |
| SCHEMBL28813221 | 0.83 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMTAAR1LMNA | |
| SCHEMBL19406117 | 0.83 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMTAAR1LMNA | |
| SCHEMBL27972864 | 0.82 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL9730065 | 0.81 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1PKMTAAR1LMNA | |
| SCHEMBL28281482 | 0.81 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL28281549 | 0.81 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1PKMTAAR1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| CN-1592743-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2005-03-09 | — | — | CN | disclosed |
| CN-1312807-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2001-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | L3MBTL1 4026/4885ALDH1A1 706/4885PKM 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.